Topline results of a phase 3 trial confirm that treatment of clinically isolated syndrome, a first attack suggestive of multiple sclerosis (MS), with teriflunomide (Aubagio, Genzyme/Sanofi) delayed conversion to clinically definite MS. This benefit of early treatment has been previously shown with the injectable agents, interferon β-1a and glatiramer acetate, but teriflunomide is the first of the oral agents to show this effect, Aaron E. Miller, MD, medical director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, at The Mount Sinai Medical Center, told Medscape Medical News. Learn more (subscription required)